CTI’s Pixuvri Flops Again At British NICE, As Discount Fails To Impress
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite a sizeable price cut, uncertainty surrounding CTI’s non-Hodgkin’s lymphoma therapy Pixuvri has landed it with a second NICE rejection.